[Biotechnologic drugs and chemotherapy for infectious diseases].
Developments in biotechnology in recent years have enabled the discovery of new pharmacological agents for the treatment and prophylaxis of infectious diseases. The agents obtained from these biotechnological procedures possess specific characteristics which significantly distinguish them from drugs obtained by chemical synthesis. These properties cover the entire development process, from investigation and production up to their administration to patients. The pharmokinetics of these preparations influence their administration routes and dosage regimens. The discovery of these drugs has led to major advances in the treatment and prophylaxis of infectious processes which until very recently had no effective treatment. The investigation and production of these drugs requires the use of highly technical resources resulting in high costs and therefore a more expensive drug on the market compared to other drugs. Nevertheless, well documented pharmoeconomic studies show that the use of this type of drug for certain symptoms may be highly cost effective. This article includes some of the possible applications of biotechnology in the infectious disease field, although the current situation indicates that more detailed and broader applications may be elaborated on in ensuing issues. The future of these drugs in chemical therapy for the treatment and prophylaxis of infectious diseases is exceedingly promising and many of these drugs are currently under laboratory investigation, more so than those under development from a chemical synthesis approach.
Honorato
J
J
Servicio de Farmacología Clínica, Clínica Universitaria de Navarra, Facultad de Medicina, Universidad de Navarra, Pamplona.
D000911:Antibodies, Monoclonal / Q000191:economics / Q000276:immunology / Q000627:therapeutic use; D001709:Biotechnology / Q000379:methods*; D003141:Communicable Diseases / Q000188:drug therapy*; D016527:Drug Costs; D015195:Drug Design; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000276:immunology / Q000627:therapeutic use; D008081:Liposomes / Q000191:economics; D016376:Oligonucleotides, Antisense / Q000191:economics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000191:economics / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic
D000911:Antibodies, Monoclonal; D015507:Drugs, Investigational; D008081:Liposomes; D016376:Oligonucleotides, Antisense; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D007372:Interferons